

**ASX / Media Release**

**19 March 2010**

---

## **RHT: Resonance Health launches MRI Cardiac Test**

Resonance Health Limited (ASX: RHT) is pleased to announce the launch of a new service to assess the risk of cardiac iron loading for patients with iron overload disorders. The test will be delivered through the Resonance Health image analysis service centre located in Perth.

This announcement expands the quantitative radiological image analysis services provided by Resonance Health to the international clinical and research communities providing additional services to the Company's established markets.

Whilst the liver is the primary site of iron storage, once a certain threshold of liver iron is exceeded iron can begin to accumulate in the heart and other organs. The assessment of an imaging parameter known as T2\* (pronounced T2 star) is widely used to provide an indirect measure of cardiac iron. The Cardiac T2\* test complements the existing FerriScan<sup>®</sup> liver iron test providing clinicians with a more comprehensive picture of the iron overload status of the patient.

FerriScan<sup>®</sup>, launched in 2005, remains the Company's core product and is currently available in over 20 countries. More than 8,000 FerriScans have been completed to date and the accurate measurement of liver iron with FerriScan<sup>®</sup> is recommended in patient management guidelines. Patients with elevated liver iron concentrations are at a greater risk of future cardiac complications and premature death. Cardiac failure due to iron overload is the leading cause of death in patients with thalassaemia major.

The Cardiac T2\* analysis service is being offered packaged with a FerriScan<sup>®</sup> liver iron test to customers located in Australia, NZ and countries covered by the CE Mark. The service will be made available to customers worldwide following necessary regulatory approvals.

By Order of the Board  
Resonance Health Limited

For further information please contact:

**Resonance Health**

Liza Dunne  
Managing Director  
T: +61 8 9286 5300  
E: lizad@ferriscan.com

Eva O'Malley  
Company Secretary  
T: +61 8 9286 5300  
E: evao@ferriscan.com

---

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company providing radiological image analysis services for the clinical and research communities. Its patented technology FerriScan<sup>®</sup> provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. The Company continues to invest in research and development into other quantitative radiological imaging technologies.